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Blockade of Renin-Angiotensin System with Angiotensin Converting Enzyme Inhibitors and Angiotensin 
Receptor Blocker Improves Vascular Distensibility in Non-Diabetic Chronic Kidney Diseases
Taku Mimura (Department of Nephrology, Saitama Medical School, Moroyama, Iruma-gun, Saitama 350 -0495, 
Japan)
　We examined the effects of angiotensin inhibition on pulse wave velocity (PWV) for the patients with non-
diabetic kidney diseases. Patients were divided into 4 groups according to their renal function and medication. 
Patients were followed for a year, and PWV was annually measured. Age, heart rate and systolic blood pressure 
correlated to PWV (R2＝0.58, p＜0.0001). Regardless of medications, patients with normal kidney function showed 
well blood pressure control (130±1/72±1 to 129±2/73±2 mmHg, n＝48) and no deterioration of renal function 
(Scr: 0.85±0.03 to 0.89±0.04 mg/dl), but only patients under angiotensin inhibition manifested a decrease in PWV 
(1914±84 to 1744±64 cm/sec, n＝40, p＜0.01). Although blood pressure was maintained below 130/80 mmHg in 
renal insufficiency patients, renal dysfunction progressed (2.21±0.11 to 2.75±0.18 mg/dl, p＜0.01, n＝43). With 
angiotensin inhibition, PWV decreased in this population (1703±64 to 1567±57 cm/sec, n＝38, p＜0.01). The 
present findings indicate that age, heart rate and systolic blood pressure constitute important determinants of 
PWV, and suggest that angiotensin blockade helps keep arterial distensibility in patients with chronic non-diabetic 
kidney diseases.
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から0.89±0.04 mg/dlまで増加したが，統計学的に有
意ではなかった（Fig. 1c）．PWVは減少した（1914±










Table 1. Patient proﬁles at the time of entry (2002)
Fig. 1. Temporal changes in serum creatinine (Scr, closed circles) and pulse wave velocity (PWV, closed triangles). Fig. 1a 
shows the patients of normal kidney function (Normal) without angiotensin inhibition (AI)(Group 1), and Fig. 1b depicts those 
of renal insufﬁciency (RI) without AI (Group 2). Fig. 1c and 1d describes Group 3 and 4, respectively. *indicates signiﬁcant 
difference from respective value.
Group 1 and 2 contains the patients with normal renal function and with renal insufficiency 
who were not under angiotensin inhibition, respectively. Group 3 and 4 comprises the patients 
with angiotensin inhibition whose renal function was normal and impaired. HR, Scr, PWV, SBP 
and DBP mean heart rate, serum creatinine, pulse wave velocity, systolic and diastolic blood 
pressure. * indicates p＜0.05.
  Group 1  Group 2  Group 3  Group 4
Age (y/o)  59.8±5.3  63.8±5.2  59.1±2.2  57.5±2.2
Sex (M/F)  6/2  3/2  28/12  27/11 
SBP (mmHg) 130±4  129±3  130±1  129±1
DBP (mmHg) 73±2  74±2  72±1  73±1
HR (beat/min) 70.5±1.5  70.8±1.2  71.4±0.4  71.6±0.4
Scr (mg/dl) 0.85±0.08  2.36±0.47* 0.85±0.03  2.16±0.12*


























Fig. 2. Positive relationship between annual changes in pulse 
wave velocity (PWV) and baseline serum creatinine (Scr). 
r=0.59, p<0.05, n=13, slope=63.9±26.2 cm/sec/year/mg/dl. 
Fig. 3. Fig. 3a depicts linear regression of pulse wave velocity 
(PWV) with age. Fig. 3b and 3c represent positive correlations 
with heart rate (HR) and systolic blood pressure (SBP). Solid 
line indicates simple regression line.
Table 2. Multiple regression analysis for PWV
SBP: systolic blood pressure, DBP: diastolic blood pressure, HR: 
heart rate, Scr: serum creatinine.
 Coefﬁcient t  p
Sex 120.5  1.52   0.13
Age 15.8  6.03  ＜0.0001
SBP 11.7  3.66  ＜0.0005
DBP −8.7  1.47  0.15
HR 16.3  4.01  ＜0.0005




R2＝0.58, F＝19.1, df 6 and 84, p＜0.0001

















































































Fig. 4. Comparisons of measured pulse wave velocity (PWV, 
closed column) against predicted PWV (open column) in 
2003. Normal kidney function is expressed as Normal, and 
RI means renal insufﬁciency. *indicates signiﬁcant difference 
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